Collecting Duct-Targeted Lipid Nanoparticles Deliver Pkd2 mRNA, Reversing ADPKD in Mice
Background
Autosomal dominant polycystic kidney disease (ADPKD) is a leading genetic cause of kidney failure, characterized by progressive cyst expansion due to mutations in PKD1 or PKD2 genes, leading to functional polycystin 1 (PC1) or polycystin 2 (PC2) deficiency. Current treatments, like tolvaptan, target downstream pathways but are limited by side effects and do not directly restore polycystin expression. Gene replacement therapy offers a direct route to functional rescue, but efficient and targeted delivery to cyst-lining renal epithelia, particularly collecting duct (CD) cells, remains a significant challenge.
Study Design
Researchers developed collecting duct (CD)-targeted lipid nanoparticles (CD LNPs) designed to deliver Pkd2 mRNA (CD-m Pkd2). These CD LNPs were compared against non-targeted formulations for renal accumulation and cell-specific targeting in vivo. The therapeutic efficacy of CD-m Pkd2 was then evaluated through repeated administration in a Pkd2-deficient mouse model of ADPKD, assessing reversal of established cystic disease, restoration of renal architecture, and reduction of fibrotic and inflammatory markers. Furthermore, a single dose of CD-m Pkd2 was tested for its ability to reduce cyst burden and improve renal function in Pkd1-deficient mouse models.
Results
The novel CD LNPs significantly increased renal accumulation and specifically targeted CD cells in vivo, outperforming non-targeted formulations in delivery efficiency. In Pkd2-deficient mouse models, repeated administration of CD-m Pkd2 induced a profound reversal of established cystic disease. This intervention successfully restored renal architecture and markedly reduced the fibrotic and inflammatory microenvironment characteristic of ADPKD. Importantly, CD-m Pkd2 was well tolerated, with no detectable off-target toxicity observed.
A single dose of CD-m Pkd2 also demonstrated significant efficacy, reducing cyst burden and improving renal function even in
Pkd1-deficient models, suggesting broad applicability across genetic backgrounds.
Key Findings
CD LNPsincreased renal accumulation and specifically targetedCDcells in vivo, outperforming non-targeted formulations.- Repeated administration of
CD-m Pkd2induced reversal of established cystic disease inPkd2-deficient mice. CD-m Pkd2restored renal architecture and reduced the fibrotic and inflammatory microenvironment.CD-m Pkd2was well tolerated without detectable off-target toxicity.- A single dose of
CD-m Pkd2reduced cyst burden and improved renal function inPkd1-deficient models.
Why It Matters
A novel gene replacement strategy for ADPKD has emerged, directly addressing the genetic defect by restoring polycystin-2 expression. This CD-m Pkd2 approach, utilizing targeted lipid nanoparticles, offers a promising solution to the critical challenge of efficient and specific delivery to renal collecting duct epithelia, a major site of cyst origin. This could lead to the first therapy that directly restores polycystin function, potentially halting or reversing disease progression in ADPKD patients. The finding that it benefits both Pkd1 and Pkd2 genetic backgrounds expands its potential impact, moving beyond current symptomatic treatments like tolvaptan that are limited by side effects and adherence issues. Further research will focus on optimizing dosing and translating this preclinical success into human trials.
adpkd
gene-therapy
lipid-nanoparticles
pkd2
pkd1
kidney-disease